Venus Medtech (Hangzhou), Inc. Class H (2500) Stock Statistics & Valuation Metrics

Venus Medtech (Hangzhou), Inc. Class H has a market cap or net worth of HK$1.27B. The enterprise value is HK$8.15B.

Venus Medtech (Hangzhou), Inc. Class H has 441,010,220 shares outstanding. The number of shares has decreased by -2.65% in one year.

Venus Medtech (Hangzhou), Inc. Class H’s return on equity (ROE) is -0.32 and return on invested capital (ROIC) is -11.40%.

The current PE Ratio of {name} is {pe}. {name}’s PEG ratio is {priceToEarningsGrowthRatio}.

In the last 12 months, Venus Medtech (Hangzhou), Inc. Class H had revenue of 470.83M and earned -714.31M in profits. Earnings per share was -1.77.

In the last 12 months, operating cash flow was 23.74M and capital expenditures -41.56M, giving a free cash flow of -17.82M billion.

Venus Medtech (Hangzhou), Inc. Class H pays an annual dividend of ―, resulting in a dividend yield of ―

Venus Medtech (Hangzhou), Inc. Class H upcoming earnings date is Aug 29, 2025, TBA (Confirmed).

Venus Medtech (Hangzhou), Inc. Class H as a current ratio of 2.22, with Debt / Equity ratio of 22.06%

In the past 12 months, Venus Medtech (Hangzhou), Inc. Class H has paid -23.34M in taxes.

Venus Medtech (Hangzhou), Inc. Class H EV to EBITDA ratio is -3.89, with an EV/FCF ratio of -133.72.

Venus Medtech (Hangzhou), Inc. Class H has HK$305.70M in cash and marketable securities with ¥369.09M in debt, giving a net cash position of HK$63.39M billion.

Gross margin is 77.25%, with operating margin of -73.61%, and net profit margin of -151.71%.

The average price target for Venus Medtech (Hangzhou), Inc. Class H is HK$2.50, which is 11.43% higher than the current price. The consensus rating is Hold